Drugs / IM23
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03585517 | Jul 2018 → Aug 2020 | acute myeloid leukemia | Beijing Immunochina Medical Science & Technology Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IM23 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03585517 ↗ |
| Modality | Cell therapy | “T Cells Expressing an Anti-CD123 Chimeric Antigen Receptor” NCT03585517 ↗ |